Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841597 | 0.85 | LMNA (0.47) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL19611955 | 0.85 | LMNA (0.47) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL254882 | 0.84 | TSHR (0.59) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL31413100 | 0.84 | TSHR (0.46) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL996468 | 0.82 | TSHR (0.57) | LMNATSHRALDH1A1HSD17B10CFTR | |
| Hydrogen Peroxide SCHEMBL28473316 | 0.82 | TSHR (0.57) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL19612032 | 0.82 | KDM4E (0.42) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL13318154 | 0.81 | LMNA (0.52) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL6653926 | 0.81 | TSHR (0.55) | LMNATSHRALDH1A1HSD17B10CFTR | |
| SCHEMBL16843152 | 0.81 | KDM4E (0.60) | LMNATSHRALDH1A1HSD17B10CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022180080-A1 | ANTI-PROLIFERATIVE AGENTS | FIRST HEALTH PHARMACEUTICALS B.V. (NL) | 2022-09-01 | — | — | WO | disclosed |
| EP-4050002-A1 | ANTI-PROLIFERATIVE AGENTS | First Health Pharmaceuticals B.V. (NL) | 2022-08-31 | — | — | EP | disclosed |
| CN-110655539-B | Method for synthesizing cis-difluoromethylcyclohexane derivatives and heterocyclic compounds by hydrogenation | 四川大学 | 2021-11-12 | — | — | CN | disclosed |
| EP-2280983-B9 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM (FR) | 2021-06-09 | — | — | EP | disclosed |
| EP-2280983-B9 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM (FR) | 2021-06-09 | — | — | EP | disclosed |
| EP-3267996-B1 | PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3268003-B1 | THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2020021024-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020021024-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR) | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | WO | disclosed |
| WO-2010037129-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009121939-A2 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM (FR) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121939-A2 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM (FR) | 2009-10-08 | — | — | WO | disclosed |
| CN-101547922-A | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists | PFIZER PRODUCT INC (US) | 2009-09-30 | — | — | CN | disclosed |
| EP-2079739-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PTH1R, VDR, P2RY1 | LMNA 4665/4885TSHR 33/4885ALDH1A1 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.